The study "Liraglutide versus placebo as an adjunct to glucose-lowering therapy in patients with type 2 diabetes and moderate renal failure" (LIRA-RENAL) did not demonstrate a benefit of liraglutide in lowering eGFR, although the duration of the study (26 weeks) may have been insufficient to show an effect
Journal of Obesity & Metabolic Syndrome, 29(2), 99109
For newcomers, the getting started with peptides guide provides a comprehensive foundation
Whether you're on your lunch break, at home in your pajamas, or squeezing it in between errands, we'll find a time that works for you
Hypersensitivity Reactions Serious and/or immediate hypersensitivity reactions have been reported
This discovery opens up a promising new approach for developing future type 2 diabetes treatments